Allergic Conjunctivitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major allergic conjunctivitis markets reached a value of US$ 2.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.7 Billion by 2034, exhibiting a growth rate (CAGR) of 2.88% during 2024-2034.
The allergic conjunctivitis market has been comprehensively analyzed in IMARC's new report titled "Allergic Conjunctivitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Allergic conjunctivitis is a condition that occurs when the conjunctiva, a thin layer of tissue covering the eye, becomes inflamed due to an allergic reaction. The most common symptoms of the ailment are itching, redness, watering, swelling of the eyes, gritty or burning sensations, etc. These indications can be present in one or both eyes and can vary in severity. In some cases, allergic conjunctivitis may cause blurred vision, light sensitivity, and a discharge from the eyes. The diagnosis of allergic conjunctivitis is usually based on the patient's symptoms and a physical examination of the eyes. The eye doctor may also ask questions about the patient's medical history, including any known allergies or family history of allergies. In some cases, additional tests, such as an allergy skin test or blood test, may be performed in order to identify the specific allergen causing the reaction. Additionally, the doctor may use a slit lamp microscope to examine the eyes and look for signs of inflammation, including swelling or redness of the conjunctiva.
The rising incidences of exposure to pollutants and chemicals owing to the elevating levels of urbanization and industrialization are primarily augmenting the allergic conjunctivitis market. In addition to this, the widespread adoption of eyedrops, such as over-the-counter antihistamine eye drops that can relieve irritation and prescription eye drops containing corticosteroids that can reduce inflammation, is creating a positive outlook for the market. Moreover, the escalating utilization of optical coherence tomography to diagnose allergic conjunctivitis, since it aids in identifying changes in the structures of the eye that are associated with inflammation, is also bolstering the market growth. Furthermore, several key players are making extensive investments in developing novel treatments that target specific inflammatory pathways in the eye to provide more effective relief of symptoms. This, in turn, is acting as another significant growth-inducing factor. Additionally, the growing popularity of refrigerated artificial tears to rinse and clean the eye due to their advantage of early relief over room temperature artificial tears is further propelling the market growth. Besides this, the ongoing development of novel ocular drug delivery systems, such as ocular inserts and drug-eluting contact lenses, which are designed to deliver medications directly to the eye in order to provide targeted and effective treatment, is expected to drive the allergic conjunctivitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the allergic conjunctivitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for allergic conjunctivitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the allergic conjunctivitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the allergic conjunctivitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the allergic conjunctivitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current allergic conjunctivitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the allergic conjunctivitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the allergic conjunctivitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the allergic conjunctivitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of allergic conjunctivitis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of allergic conjunctivitis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of allergic conjunctivitis by gender across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of allergic conjunctivitis by type across the seven major markets?
How many patients are diagnosed (?2018-2034?) with allergic conjunctivitis across the seven major markets?
What is the size of the allergic conjunctivitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of allergic conjunctivitis?
What will be the growth rate of patients across the seven major markets?
Allergic Conjunctivitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for allergic conjunctivitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the allergic conjunctivitis market?
What are the key regulatory events related to the allergic conjunctivitis market?
What is the structure of clinical trial landscape by status related to the allergic conjunctivitis market?
What is the structure of clinical trial landscape by phase related to the allergic conjunctivitis market?
What is the structure of clinical trial landscape by route of administration related to the allergic conjunctivitis market?
The allergic conjunctivitis market has been comprehensively analyzed in IMARC's new report titled "Allergic Conjunctivitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Allergic conjunctivitis is a condition that occurs when the conjunctiva, a thin layer of tissue covering the eye, becomes inflamed due to an allergic reaction. The most common symptoms of the ailment are itching, redness, watering, swelling of the eyes, gritty or burning sensations, etc. These indications can be present in one or both eyes and can vary in severity. In some cases, allergic conjunctivitis may cause blurred vision, light sensitivity, and a discharge from the eyes. The diagnosis of allergic conjunctivitis is usually based on the patient's symptoms and a physical examination of the eyes. The eye doctor may also ask questions about the patient's medical history, including any known allergies or family history of allergies. In some cases, additional tests, such as an allergy skin test or blood test, may be performed in order to identify the specific allergen causing the reaction. Additionally, the doctor may use a slit lamp microscope to examine the eyes and look for signs of inflammation, including swelling or redness of the conjunctiva.
The rising incidences of exposure to pollutants and chemicals owing to the elevating levels of urbanization and industrialization are primarily augmenting the allergic conjunctivitis market. In addition to this, the widespread adoption of eyedrops, such as over-the-counter antihistamine eye drops that can relieve irritation and prescription eye drops containing corticosteroids that can reduce inflammation, is creating a positive outlook for the market. Moreover, the escalating utilization of optical coherence tomography to diagnose allergic conjunctivitis, since it aids in identifying changes in the structures of the eye that are associated with inflammation, is also bolstering the market growth. Furthermore, several key players are making extensive investments in developing novel treatments that target specific inflammatory pathways in the eye to provide more effective relief of symptoms. This, in turn, is acting as another significant growth-inducing factor. Additionally, the growing popularity of refrigerated artificial tears to rinse and clean the eye due to their advantage of early relief over room temperature artificial tears is further propelling the market growth. Besides this, the ongoing development of novel ocular drug delivery systems, such as ocular inserts and drug-eluting contact lenses, which are designed to deliver medications directly to the eye in order to provide targeted and effective treatment, is expected to drive the allergic conjunctivitis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the allergic conjunctivitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for allergic conjunctivitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the allergic conjunctivitis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the allergic conjunctivitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the allergic conjunctivitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current allergic conjunctivitis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the allergic conjunctivitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the allergic conjunctivitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the allergic conjunctivitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of allergic conjunctivitis across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of allergic conjunctivitis by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of allergic conjunctivitis by gender across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of allergic conjunctivitis by type across the seven major markets?
How many patients are diagnosed (?2018-2034?) with allergic conjunctivitis across the seven major markets?
What is the size of the allergic conjunctivitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of allergic conjunctivitis?
What will be the growth rate of patients across the seven major markets?
Allergic Conjunctivitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for allergic conjunctivitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the allergic conjunctivitis market?
What are the key regulatory events related to the allergic conjunctivitis market?
What is the structure of clinical trial landscape by status related to the allergic conjunctivitis market?
What is the structure of clinical trial landscape by phase related to the allergic conjunctivitis market?
What is the structure of clinical trial landscape by route of administration related to the allergic conjunctivitis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ALLERGIC CONJUNCTIVITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ALLERGIC CONJUNCTIVITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ALLERGIC CONJUNCTIVITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 ALLERGIC CONJUNCTIVITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ALLERGIC CONJUNCTIVITIS - UNMET NEEDS
10 ALLERGIC CONJUNCTIVITIS - KEY ENDPOINTS OF TREATMENT
11 ALLERGIC CONJUNCTIVITIS - MARKETED PRODUCTS
11.1 List of Allergic Conjunctivitis Marketed Drugs Across the Top 7 Markets
11.1.1 Zaditor (Ketotifen fumarate ophthalmic) - Novartis Ophthalmics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Bepreve (Bepotastine besilate) - Mitsubishi Tanabe Pharma Corporation
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Elestat (Epinastine ophthalmic) - AbbVie
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Lastacaft (Alcaftadine) - AbbVie
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Alocril (Nedocromil ophthalmic) - AbbVie
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ALLERGIC CONJUNCTIVITIS - PIPELINE DRUGS
12.1 List of Allergic Conjunctivitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Reproxalap - Aldeyra Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 VSJ 110 - Vanda Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ST266 - Noveome
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ALLERGIC CONJUNCTIVITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ALLERGIC CONJUNCTIVITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ALLERGIC CONJUNCTIVITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Allergic Conjunctivitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Allergic Conjunctivitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Allergic Conjunctivitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Allergic Conjunctivitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Allergic Conjunctivitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Allergic Conjunctivitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Allergic Conjunctivitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Allergic Conjunctivitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Allergic Conjunctivitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Allergic Conjunctivitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Allergic Conjunctivitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Allergic Conjunctivitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Allergic Conjunctivitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Allergic Conjunctivitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Allergic Conjunctivitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Allergic Conjunctivitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Allergic Conjunctivitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Allergic Conjunctivitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Allergic Conjunctivitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Allergic Conjunctivitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Allergic Conjunctivitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Allergic Conjunctivitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Allergic Conjunctivitis - Access and Reimbursement Overview
16 ALLERGIC CONJUNCTIVITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ALLERGIC CONJUNCTIVITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ALLERGIC CONJUNCTIVITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ALLERGIC CONJUNCTIVITIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 ALLERGIC CONJUNCTIVITIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ALLERGIC CONJUNCTIVITIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Epidemiology by Type (?2018-2034?)
7.2.6 Diagnosed Cases (?2018-2034?)
7.2.7 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Epidemiology by Type (?2018-2034?)
7.3.6 Diagnosed Cases (?2018-2034?)
7.3.7 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Epidemiology by Type (?2018-2034?)
7.4.6 Diagnosed Cases (?2018-2034?)
7.4.7 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Epidemiology by Type (?2018-2034?)
7.5.6 Diagnosed Cases (?2018-2034?)
7.5.7 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Epidemiology by Type (?2018-2034?)
7.6.6 Diagnosed Cases (?2018-2034?)
7.6.7 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Epidemiology by Type (?2018-2034?)
7.7.6 Diagnosed Cases (?2018-2034?)
7.7.7 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Epidemiology by Type (?2018-2034?)
7.8.6 Diagnosed Cases (?2018-2034?)
7.8.7 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Epidemiology by Type (?2018-2034?)
7.9.6 Diagnosed Cases (?2018-2034?)
7.9.7 Patient Pool/Treated Cases (?2018-2034?)
8 ALLERGIC CONJUNCTIVITIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ALLERGIC CONJUNCTIVITIS - UNMET NEEDS
10 ALLERGIC CONJUNCTIVITIS - KEY ENDPOINTS OF TREATMENT
11 ALLERGIC CONJUNCTIVITIS - MARKETED PRODUCTS
11.1 List of Allergic Conjunctivitis Marketed Drugs Across the Top 7 Markets
11.1.1 Zaditor (Ketotifen fumarate ophthalmic) - Novartis Ophthalmics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Bepreve (Bepotastine besilate) - Mitsubishi Tanabe Pharma Corporation
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Elestat (Epinastine ophthalmic) - AbbVie
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Lastacaft (Alcaftadine) - AbbVie
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Alocril (Nedocromil ophthalmic) - AbbVie
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 ALLERGIC CONJUNCTIVITIS - PIPELINE DRUGS
12.1 List of Allergic Conjunctivitis Pipeline Drugs Across the Top 7 Markets
12.1.1 Reproxalap - Aldeyra Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 VSJ 110 - Vanda Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ST266 - Noveome
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. ALLERGIC CONJUNCTIVITIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. ALLERGIC CONJUNCTIVITIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 ALLERGIC CONJUNCTIVITIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Allergic Conjunctivitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Allergic Conjunctivitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Allergic Conjunctivitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Allergic Conjunctivitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Allergic Conjunctivitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Allergic Conjunctivitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Allergic Conjunctivitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Allergic Conjunctivitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Allergic Conjunctivitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Allergic Conjunctivitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Allergic Conjunctivitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Allergic Conjunctivitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Allergic Conjunctivitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Allergic Conjunctivitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Allergic Conjunctivitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Allergic Conjunctivitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Allergic Conjunctivitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Allergic Conjunctivitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Allergic Conjunctivitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Allergic Conjunctivitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Allergic Conjunctivitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Allergic Conjunctivitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Allergic Conjunctivitis - Access and Reimbursement Overview
16 ALLERGIC CONJUNCTIVITIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 ALLERGIC CONJUNCTIVITIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 ALLERGIC CONJUNCTIVITIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
